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Coronavirus Disease 2019 (COVID-19), due to infection 
with the virus termed SARS-CoV-2, has complicated the 
evaluation of elevated liver enzymes. Elevated liver enzymes 
occur in a median of 15% [1] and up to 58% [2] of patients 
with COVID-19. Though the most common patterns of liver 
enzyme abnormalities in patients with SARS-CoV-2 include 
elevated aminotransferases, with aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT) typically 1–2 
times the upper limit of normal [2], the prognostic signifi-
cance of abnormal liver biochemistries remains uncertain. 
There are many potential contributing etiologies to elevated 
liver enzymes in patients with SARS-CoV-2 including direct 
liver injury, associated inflammatory responses, congestive 
hepatopathy, hepatic ischemia, drug-induced liver injury 
(DILI), and muscle breakdown [3, 4]. In one meta-analysis, 
an estimated 3% of patients had recognized chronic liver 
disease at the time of COVID-19 infection [5]. As a result, 
consultations for abnormal liver biochemistries in patients 
with COVID-19 are likely common and difficult to resolve. 
Clarifying a diagnosis is further complicated by the desire 
to limit exposure of staff assisting with or performing diag-
nostic testing (e.g., abdominal ultrasound or liver biopsy). 
In this context, there is need for more information on how 
best to evaluate these patients.
In the current issue of Digestive Diseases and Sciences, 
Bloom et al. [6] demonstrate the diagnostic difficulties of 
evaluating elevated liver enzymes in patients with COVID-
19. The authors identified twenty adult inpatients at Massa-
chusetts General and Brigham and Women’s Hospitals who
were PCR-positive for SARS-CoV-2 and received inpatient
hepatology consultations for abnormal liver biochemistries.
Laboratory and clinical data were retrospectively reviewed 
by three senior hepatologists who assigned a rank-order list 
of the top three potential etiologies, providing recommenda-
tions for additional evaluations. Patients with COVID-19 in 
this study were middle-aged (median 46 years), 90% male, 
55% Hispanic, and 40% had underlying chronic liver disease. 
Most had a hepatocellular (64%) or cholestatic (29%) pattern 
of liver biochemistries. Blood chemistries reflective of liver 
synthetic function were generally normal. The most com-
mon diagnoses for these patients were COVID-related liver 
injury and DILI, but agreement on the most likely diagnosis 
was low among the three hepatologists and the original con-
sultant (κ agreement 0.10). Conversely, all were in general 
agreement with the diagnostic work-up, which included liver 
enzyme monitoring for all patients. Abdominal ultrasound 
was recommended for a minority and was often discouraged. 
Similarly, cross-sectional imaging and liver biopsy were not 
recommended for any patients.
This investigation of the diagnosis and work-up of ele-
vated liver enzymes in patients with COVID-19 provides a 
timely glimpse into the difficulties encountered caring for 
these patients. However, study results should be interpreted 
in the context of potential limitations. This study included 
a small patient sample, and results may lack generalizabil-
ity to other settings given that it was conducted at a large 
academic medical center early in the US COVID-19 epi-
demic (March–April 2020), when understanding of the 
hepatic effects of SARS-CoV-2 was limited. Furthermore, 
restricting this cohort to patients with a hepatology consul-
tation may have selected for more complex patients, which 
could account for the large proportion of included patients 
with chronic liver disease. Lastly, without follow-up data in 
these patients, it is impossible to evaluate the accuracy of 
the ranked diagnoses.
These potential limitations do not diminish the immediate 
clinical implications of this study. These results underscore 
the immense diagnostic challenge of elevated liver enzymes 
in COVID-19, given the large degree of disagreement among 
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senior hepatologists at a tertiary academic medical center. 
The majority of COVID-19 patients receive care at non-
academic medical centers without access to hepatology con-
sultation. Therefore, guidance on a streamlined approach to 
evaluate these patients is essential.
The current consensus statements from GI and liver soci-
eties endorse a thorough evaluation for alternative etiolo-
gies of elevated liver enzymes in patients with COVID-19 
and consideration of liver enzyme monitoring during hos-
pitalization [1, 2]. There is no current recommendation for 
or against liver biopsy for patients with COVID-19 who 
develop acute liver injury. For the time being, however, liver 
biopsy should rarely be used for the evaluation of abnormal 
liver biochemistries in patients with COVID-19 for a number 
of reasons:
First, no specific histopathological findings in patients 
with COVID-19 have emerged [3] and many centers may 
not have an experienced liver pathologist. There is one 
report of possible coronavirus particles in hepatocyte 
cytoplasm [7], which may suggest direct viral infection, 
but it is possible that these findings are due to autolysis 
rather than direct viral inclusions [8]. Given the lack of 
histopathological findings specific to COVID-related liver 
injury, the primary benefit of biopsy would be to rule out 
alternative etiologies of liver injury, which can generally 
be evaluated without the need for liver biopsy.
Second, liver biopsy is unlikely to lead to a change in 
management or provide prognostic information. In this 
study by Bloom et al., there was broad agreement among 
included hepatologists regarding diagnostic evaluation, 
suggesting that the diagnosis did not have a strong bear-
ing on follow-up recommendations. Furthermore, there 
have been inconsistent findings regarding the prognos-
tic importance of elevated liver enzymes in COVID-19 
[9]. It is likely that well-established risk factors, such 
as age and medical comorbidities (including cirrhosis), 
are more important predictors of COVID-19 outcomes 
than are liver biochemistries. Moreover, in a recent large 
cohort study of hospitalized patients with COVID-19, the 
prevalence of severe acute liver injury was exceedingly 
low [10].
Third, the potential risks of liver biopsy for COVID-19 
will extend to both patient and staff. Procedural risks of 
liver biopsy include hemorrhagic complications, biliary 
injury, pneumothorax, and even death. For patients with 
COVID-19, there are added risks of SARS-CoV-2 trans-
mission to ancillary staff members involved in patient 
transportation or in procedure areas where biopsies are 
performed. For the vast majority of patients, these risks 
will likely outweigh its uncertain benefits.
In conclusion, this study by Bloom et al. reports that, 
early in the COVID-19 pandemic, there was significant 
disagreement among senior hepatologists with regard to 
the cause of abnormal liver biochemistries in a small group 
of SARS-CoV-2 infected patients, but consistency with 
regard to follow-up recommendations. As demonstrated in 
this study, a diagnostic approach for elevated liver enzymes 
in COVID-19 should include: (1) thorough evaluation of 
alcohol and medication use, (2) laboratory assessment of 
liver synthetic function and portal hypertension (i.e., plate-
let count, albumin, PT/INR), (3) serological and virologi-
cal testing in order to exclude common prevalent liver dis-
eases such as viral hepatitis, (4) ongoing monitoring of liver 
enzymes, (5) imaging reserved for patients with high pre-test 
probability of biliary obstruction or thrombosis, and (6) liver 
biopsy in rare cases when results may change care (e.g., to 
assess for rejection in a post-liver transplant patient). We 
applaud ongoing efforts to provide guidance on the manage-
ment of patients with COVID-19, given that best practices 
will evolve along with our understanding of SARS-CoV-2.
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